JP7428696B2 - 抗体による癌治療 - Google Patents

抗体による癌治療 Download PDF

Info

Publication number
JP7428696B2
JP7428696B2 JP2021506746A JP2021506746A JP7428696B2 JP 7428696 B2 JP7428696 B2 JP 7428696B2 JP 2021506746 A JP2021506746 A JP 2021506746A JP 2021506746 A JP2021506746 A JP 2021506746A JP 7428696 B2 JP7428696 B2 JP 7428696B2
Authority
JP
Japan
Prior art keywords
seq
antibody
cancer
anx
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021506746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534121A5 (enExample
JP2021534121A (ja
Inventor
バリー ウッド、クリストファー
シー． フラタウ、ティナ
デンプシー、フィオナ
クライトン、スコット
Original Assignee
メダネックス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メダネックス エルティーディー． filed Critical メダネックス エルティーディー．
Publication of JP2021534121A publication Critical patent/JP2021534121A/ja
Publication of JP2021534121A5 publication Critical patent/JP2021534121A5/ja
Priority to JP2024000815A priority Critical patent/JP7728035B2/ja
Application granted granted Critical
Publication of JP7428696B2 publication Critical patent/JP7428696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021506746A 2018-08-10 2019-08-12 抗体による癌治療 Active JP7428696B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000815A JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1813137.5A GB201813137D0 (en) 2018-08-10 2018-08-10 Cancer treatment with an antibody
GB1813137.5 2018-08-10
PCT/EP2019/071627 WO2020030827A1 (en) 2018-08-10 2019-08-12 Cancer treatment with an antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000815A Division JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Publications (3)

Publication Number Publication Date
JP2021534121A JP2021534121A (ja) 2021-12-09
JP2021534121A5 JP2021534121A5 (enExample) 2022-08-18
JP7428696B2 true JP7428696B2 (ja) 2024-02-06

Family

ID=63667034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506746A Active JP7428696B2 (ja) 2018-08-10 2019-08-12 抗体による癌治療
JP2024000815A Active JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000815A Active JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Country Status (12)

Country Link
US (1) US11858982B2 (enExample)
EP (1) EP3833404A1 (enExample)
JP (2) JP7428696B2 (enExample)
KR (1) KR20210088523A (enExample)
CN (1) CN112770786B (enExample)
AU (1) AU2019319092B2 (enExample)
BR (1) BR112021002435A2 (enExample)
GB (1) GB201813137D0 (enExample)
IL (1) IL280421B2 (enExample)
MX (1) MX2021001604A (enExample)
TW (1) TW202014437A (enExample)
WO (1) WO2020030827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250025553A1 (en) 2021-11-18 2025-01-23 Medannex Ltd. Combination therapy for cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534914A (ja) 2010-06-09 2013-09-09 クイーン マリー アンド ウエストフィールド カレッジ、ユニバーシティ オブ ロンドン アネキシン１抗体
US20150086553A1 (en) 2013-09-10 2015-03-26 Samsung Electronics Co., Ltd. Polypeptide binding to annexin a1 and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219299A1 (en) 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
US20040219572A1 (en) 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
EP1670510A1 (en) 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
CN100571785C (zh) * 2006-09-06 2009-12-23 中国医学科学院北京协和医院 Annexin A3与癌症的铂类化疗药物耐药性的相关性
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
CN102898527B (zh) 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
US20160291025A1 (en) 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
US20210292400A1 (en) 2018-05-17 2021-09-23 Yiping W. Han Methods for treating, preventing and detecting the prognosis of colorectal cancer
US20210353721A1 (en) 2018-08-07 2021-11-18 The Brigham And Women's Hospital, Inc. Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1
US20200171165A1 (en) 2018-11-30 2020-06-04 Proteogenomics Research Institute for Systems Medicine Enhanced targeted delivery of therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534914A (ja) 2010-06-09 2013-09-09 クイーン マリー アンド ウエストフィールド カレッジ、ユニバーシティ オブ ロンドン アネキシン１抗体
US20150086553A1 (en) 2013-09-10 2015-03-26 Samsung Electronics Co., Ltd. Polypeptide binding to annexin a1 and use thereof

Also Published As

Publication number Publication date
BR112021002435A2 (pt) 2021-05-04
US11858982B2 (en) 2024-01-02
CA3107674A1 (en) 2020-02-13
KR20210088523A (ko) 2021-07-14
EP3833404A1 (en) 2021-06-16
CN112770786B (zh) 2023-10-27
CN112770786A (zh) 2021-05-07
JP2024041851A (ja) 2024-03-27
TW202014437A (zh) 2020-04-16
WO2020030827A1 (en) 2020-02-13
MX2021001604A (es) 2021-04-19
US20210238269A1 (en) 2021-08-05
IL280421A (en) 2021-03-25
JP2021534121A (ja) 2021-12-09
GB201813137D0 (en) 2018-09-26
IL280421B2 (en) 2024-06-01
AU2019319092A1 (en) 2021-03-18
AU2019319092B2 (en) 2026-04-02
JP7728035B2 (ja) 2025-08-22
IL280421B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2022179611A (ja) 抗ｃｔｌａ４抗体及びその用途
JP7110369B2 (ja) 抗ｐｄ－１抗体及びその用途
JP7479281B2 (ja) 抗ｏｘ４０抗体及びその用途
AU2015366213A1 (en) Anti-Axl antagonistic antibodies
JP7728035B2 (ja) 抗体による癌治療
CA3107674C (en) Cancer treatment with an antibody
US20250025553A1 (en) Combination therapy for cancer
CN118524851A (zh) 用于癌症的组合疗法
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40098451A (zh) 抗ccr8单克隆抗体及其用途
CN121889427A (zh) 抗tigit抗体及其用途
HK40039579A (en) Anti-ox40 antibodies and uses thereof
HK40047604B (zh) 抗cd40抗体及其用途
HK40039579B (en) Anti-ox40 antibodies and uses thereof
HK40040324A (zh) 抗pd-1抗体及其用途
HK40050386B (en) Anti-pd-1 antibodies and uses thereof
HK40040324B (en) Anti-pd-1 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240125

R150 Certificate of patent or registration of utility model

Ref document number: 7428696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150